To the Editor We congratulate zu Eulenburg et al 1 for their longitudinal study of postspaceflight changes in blood-based biomarkers in 5 cosmonauts. Unlike a previous study, which used magnetic resonance imaging to evaluate the neurologic changes after spaceflight in cosmonauts, 2 blood-based biomarkers may present a practical breakthrough in monitoring neurologic health in real time in space on successful validation of the current findings. Their findings are remarkable in that several biomarkers (eg, neurofilament light chain [NfL], glial fibrillary acidic protein [GFAP], amyloid-β proteins 42 and 40) showed elevations postspaceflight compared with prespaceflight. However, there are several key limitations that we thought were worth highlighting to the JAMA Neurology readership.The sample size was small (n = 5), and results need to be replicated in a larger sample. However, the time-course patterns of select biomarkers showed an interesting quadratic trend, where most biomarkers peaked at 1 week postspaceflight and began returning to baseline level at 3 weeks postspaceflight. This pattern poses a question as to whether it is the long stay in space (average of 6 months) or the sudden change from microgravity in space to gravity on earth that triggers the elevations of blood biomarkers. If the former is correct, degenerative cellular responses to microgravity would have been progressive during the 6-month space mission, and biomarker levels at 1 day postspaceflight would have shown more remarkable changes from prespaceflight, instead of gradually increasing upon their return. The latter is also plausible because returning from space is a very stressful experience on the body, 3 possibly triggering an inflammatory response, and microstructural components of the brain must readapt to gravity on earth. Given that NfL and GFAP are sensitive to very mild subconcussive head impacts (eg, soccer heading), 4,5 their elevations may be due to the crossing effect of nongravity to gravity. Blood sampling during the space mission would have addressed this issue.It would also be paramount to understand why the biomarker time series of some individuals showed minimal from spaceflight whereas others exhibited continued elevation up to 3 weeks postspaceflight. A larger-scale multinational study in cosmonauts will allow stratification of additional factors, such as sex, age, genetic variance, years of spaceflight training, number of space missions, and any preexisting comorbidities. With plans for longer-duration spaceflights and recent developments in civilian access to space, delineating the neurologic consequences of spaceflight is critical, and we look forward to continued investigations of the effects of spaceflight on neurologic health using bloodbased biomarkers.